PLC expects US de-listing after standards failings
This article was originally published in Clinica
Cardiac and vascular product developer PLC Systems has said it expects to be de-listed from the American Stock Exchange (AMEX) sometime in the coming weeks as it has failed to prove its ability to regain compliance with listing standards. Franklin, Massachusetts-based PLC said its shareholder equity was less than $4m as of June 30 2008, and it incurred losses from continuing operations and net losses in three out of the four most recent fiscal years. The firm, which has been trading at less than $1 per share since September 2006, now expects to begin trading on the over-the-counter bulletin board.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals